New York Said to Probe Insurers Over Hepatitis C DrugsBy and
State attorney general probes limited access to treatments
Gilead, AbbVie drugs cost about $1,000 a pill before discounts
The New York state attorney general has asked 16 health insurance companies for information on their coverage of hepatitis C treatments, amid concerns that some companies are restricting coverage of the expensive medications, according to a person familiar with the investigation.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.